Compounds > brl 42810
Page last updated: 2024-10-26

brl 42810 and Chickenpox

brl 42810 has been researched along with Chickenpox in 10 studies

Chickenpox: A highly contagious infectious disease caused by the varicella-zoster virus (HERPESVIRUS 3, HUMAN). It usually affects children, is spread by direct contact or respiratory route via droplet nuclei, and is characterized by the appearance on the skin and mucous membranes of successive crops of typical pruritic vesicular lesions that are easily broken and become scabbed. Chickenpox is relatively benign in children, but may be complicated by pneumonia and encephalitis in adults. (From Dorland, 27th ed)

Research Excerpts

ExcerptRelevanceReference
"Two multicenter, open-label, single-arm, two-phase studies evaluated single-dose pharmacokinetics and single- and multiple-dose safety of a pediatric oral famciclovir formulation (prodrug of penciclovir) in children aged 1 to 12 years with suspicion or evidence of herpes simplex virus (HSV) or varicella-zoster virus (VZV) infection."5.14Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection. ( Abrams, B; Arguedas, A; Bomgaars, L; De León Castrejón, T; Hamed, K; Kaiser, G; Looby, M; Roberts, M; Rodriguez, A; Sáez-Llorens, X; Spigarelli, MG; Yogev, R; Zhou, W, 2009)
"Reactivation of varicella zoster virus (VZV) is a common event in patients undergoing allogeneic bone marrow transplantation (BMT) and may lead to life-threatening complications."2.69Varicella zoster virus infections following allogeneic bone marrow transplantation: frequency, risk factors, and clinical outcome. ( Akhtar, M; DesJardin, J; Griffith, J; Koc, Y; Miller, KB; Schenkein, DP; Snydman, DR, 2000)
"We examined the incidence of herpes varicella-zoster virus (VZV) infection in 151 patients undergoing allogeneic BMT between August 1990 and September 1997 and who survived at least 3 months."2.69Varicella-zoster infection after allogeneic bone marrow transplantation: incidence, risk factors and prevention with low-dose aciclovir and ganciclovir. ( Beresford, JA; Grigg, A; Matthews, JP; Sasadeusz, J; Steer, CB; Szer, J, 2000)
" Famciclovir and valacyclovir demonstrate superior pharmacokinetics compared with acyclovir and allow for less frequent daily dosing with higher achievable serum drug concentrations."2.40Management of herpes simplex and varicella-zoster virus infections. ( Erlich, KS, 1997)

Research

Studies (10)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's5 (50.00)18.2507
2000's5 (50.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Sáez-Llorens, X1
Yogev, R1
Arguedas, A1
Rodriguez, A1
Spigarelli, MG1
De León Castrejón, T1
Bomgaars, L1
Roberts, M1
Abrams, B1
Zhou, W1
Looby, M1
Kaiser, G1
Hamed, K1
Brown, TJ1
McCrary, M1
Tyring, SK1
Ioannidis, J1
Wilkinson, D1
Easterbrook, P1
Wood, MJ1
Erlich, KS1
Wutzler, P1
Whitley, RJ1
Zeller, V1
Caumes, E1
Bricaire, F1
Koc, Y1
Miller, KB1
Schenkein, DP1
Griffith, J1
Akhtar, M1
DesJardin, J1
Snydman, DR1
Steer, CB1
Szer, J1
Sasadeusz, J1
Matthews, JP1
Beresford, JA1
Grigg, A1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Pharmacokinetics and Safety of Famciclovir Oral Pediatric Formulation in Children 1-12 Years of Age With Varicella Zoster Infection[NCT00098046]Phase 376 participants (Anticipated)Interventional2005-07-31Completed
A Multicenter, Open-label, Single-arm, Two-step Study to Evaluate the Safety and Single-dose Pharmacokinetics of Famciclovir and Multiple-dose Safety After Administration of Famciclovir Oral Pediatric Formulation to Children 1 to 12 Years of Age With Herp[NCT00098059]Phase 374 participants (Actual)Interventional2005-02-28Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Apparent Oral Clearance of Penciclovir (CL/F)

PK parameter; penciclovir is the active metabolite of famciclovir. (NCT00098059)
Timeframe: Plasma level measurements: pre-dose, 1, 2, 3, 4 and 5 hours post-dose

InterventionL/h (Mean)
1 to < 2 Years20.8
2 to <6 Years25.1
6 to <=12 Years43.7
13 to <= 18 Years68.8

Apparent Terminal Elimination Half-life of Penciclovir (T1/2)

PK parameter; penciclovir is the active metabolite of famciclovir (NCT00098059)
Timeframe: Plasma level measurements: pre-dose, 1, 2, 3, 4 and 5 hours post-dose

Interventionhours (Mean)
1 to < 2 Years1.09
2 to <6 Years1.36
6 to <=12 Years1.60
13 to <= 18 Years1.86

Area Under the Penciclovir Plasma Concentration-time Curve From Time 0 to Infinity (AUC0-∞)

PK parameter; penciclovir is the active metabolite of famciclovir. (NCT00098059)
Timeframe: Plasma level measurements: pre-dose, 1, 2, 3, 4 and 5 hours post-dose

Intervention(μg/mL)h (Mean)
1 to < 2 Years6.17
2 to <6 Years6.85
6 to <=12 Years8.15
13 to <= 18 Years5.93

Maximum Observed Plasma Concentration of Penciclovir (Cmax)

PK parameter; penciclovir is the active metabolite of famciclovir. (NCT00098059)
Timeframe: plasma level measurements: pre-dose, 1, 2, 3, 4 and 5 hours post-dose

Interventionμg/mL (Mean)
1 to < 2 Years2.84
2 to <6 Years2.44
6 to <=12 Years2.82
13 to <= 18 Years1.89

Time of Maximum Observed Plasma Concentration of Penciclovir (Tmax)

PK parameter; penciclovir is the active metabolite of famciclovir. (NCT00098059)
Timeframe: Plasma level measurements: pre-dose, 1, 2, 3, 4 and 5 hours post-dose

Interventionhours (Median)
1 to < 2 Years1.21
2 to <6 Years1.07
6 to <=12 Years1.00
13 to < =18 Years1.47

Overall Acceptability of Pediatric Oral Formulation by Patients in Part A of the Study.

Overall acceptability of the study medication was determined by caretaker response. (NCT00098059)
Timeframe: Day 1, after swallowing the dose.

,,,
Interventionparticipants (Number)
BadlyNeither bad nor goodWell
1 to < 2 Years112
13 to <=18 Years200
2 to <6 Years418
6 to <13 Years044

Overall Acceptability of Pediatric Oral Formulation by Patients in Part B of the Study

Overall acceptability of study medication was determined by caretaker response. (NCT00098059)
Timeframe: Day 8 at home: after swallowing last dose

,,
Interventionparticipants (Number)
BadlyNeither bad nor goodWell
1 to < 2 Years733
2 to <6 Years537
6 to <13 Years3311

Overall Acceptability of Pediatric Oral Formulation by Patients in Part B of the Study.

Overall acceptability of the study medication was determined by caretaker response. (NCT00098059)
Timeframe: Day 1 at clinic: after swallowing first dose

,,
Interventionparticipants (Number)
BadlyNeither bad nor goodWell
1 to < 2 Years922
2 to <6 Years619
6 to <13 Years729

Safety and Tolerability of a Single-dose of Famciclovir in Part A of the Study.

A patient with multiple adverse events (AEs) within the primary system organ class is counted only once in total row. (NCT00098059)
Timeframe: 8 hours and 24 hours after study drug administration (Part A)

,,,
Interventionparticipants (Number)
Patients with AEsGastrointestinal disordersNervous system disordersGeneral disorders and administration siteInfections and infestationsSkin and subcutaneous tissue disorders
1 to < 2 Years000000
13 to <= 18 Years211100
2 to <6 Years210011
6 to <=12 Years101000

Safety and Tolerability of Famciclovir Pediatric Oral Formulation in Part B of the Study.

A patient with multiple AEs within the primary system organ class is counted only once in total row. (NCT00098059)
Timeframe: Administered 2 times daily over 7 days

,,
Interventionparticipants (Number)
Patients with AEsGastrointestinal disordersNervous system disordersGeneral disorders and administration siteRespiratory, thoracic and mediastinal disordersInfections and infestationsSkin and subcutaneous tissue disordersVascular disordersInjury, poisoning and procedural complicationsInvestigationsMetabolism and nutrition disorders
1 to < 2 Years64031310011
2 to <6 Years83211020100
6 to <13 Years126512002100

Reviews

7 reviews available for brl 42810 and Chickenpox

ArticleYear
Antiviral agents: Non-antiretroviral [correction of Nonantiviral] drugs.
    Journal of the American Academy of Dermatology, 2002, Volume: 47, Issue:4

    Topics: 2-Aminopurine; Acyclovir; Antiviral Agents; Chickenpox; Cytomegalovirus Infections; Famciclovir; Fos

2002
HIV: prevention of opportunistic infections.
    Clinical evidence, 2005, Issue:13

    Topics: 2-Aminopurine; Acyclovir; AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Anti-HIV Age

2005
Successors to acyclovir.
    The Journal of antimicrobial chemotherapy, 1994, Volume: 34, Issue:3

    Topics: 2-Aminopurine; Acyclovir; Antiviral Agents; Arabinofuranosyluracil; Chickenpox; Drug Resistance, Mic

1994
Management of herpes simplex and varicella-zoster virus infections.
    The Western journal of medicine, 1997, Volume: 166, Issue:3

    Topics: 2-Aminopurine; Acyclovir; Adult; Antiviral Agents; Chickenpox; Child; Famciclovir; Female; Herpes Si

1997
Antiviral therapy of herpes simplex and varicella-zoster virus infections.
    Intervirology, 1997, Volume: 40, Issue:5-6

    Topics: 2-Aminopurine; Acyclovir; Administration, Oral; Antiviral Agents; Arabinofuranosyluracil; Bromodeoxy

1997
Approaches to the treatment of varicella-zoster virus infections.
    Contributions to microbiology, 1999, Volume: 3

    Topics: 2-Aminopurine; Acyclovir; Adrenal Cortex Hormones; Antiviral Agents; Chickenpox; Famciclovir; Guanin

1999
[Varicella and zona: epidemiology, physiopathology, diagnosis, course, treatment].
    La Revue du praticien, 1999, Nov-15, Volume: 49, Issue:18

    Topics: 2-Aminopurine; Acyclovir; Adult; Aged; Antiviral Agents; Chickenpox; Child; Child, Preschool; Diagno

1999

Trials

3 trials available for brl 42810 and Chickenpox

ArticleYear
Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection.
    Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:5

    Topics: 2-Aminopurine; Acyclovir; Antiviral Agents; Chickenpox; Child; Child, Preschool; Drug Administration

2009
Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection.
    Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:5

    Topics: 2-Aminopurine; Acyclovir; Antiviral Agents; Chickenpox; Child; Child, Preschool; Drug Administration

2009
Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection.
    Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:5

    Topics: 2-Aminopurine; Acyclovir; Antiviral Agents; Chickenpox; Child; Child, Preschool; Drug Administration

2009
Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection.
    Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:5

    Topics: 2-Aminopurine; Acyclovir; Antiviral Agents; Chickenpox; Child; Child, Preschool; Drug Administration

2009
Varicella zoster virus infections following allogeneic bone marrow transplantation: frequency, risk factors, and clinical outcome.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2000, Volume: 6, Issue:1

    Topics: 2-Aminopurine; Acyclovir; Adolescent; Adult; Antiviral Agents; Bone Marrow Transplantation; Chickenp

2000
Varicella-zoster infection after allogeneic bone marrow transplantation: incidence, risk factors and prevention with low-dose aciclovir and ganciclovir.
    Bone marrow transplantation, 2000, Volume: 25, Issue:6

    Topics: 2-Aminopurine; Acyclovir; Adolescent; Adult; Age of Onset; Aged; Analysis of Variance; Antiviral Age

2000